Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?

摘要

In the August, 2010, issue of The Lancet Oncology, Wendy De Roock and colleagues1 analysis of almost 900 patients with chemotherapy-refractory metastatic colorectal cancer assessed the role of KRAS, BRAF, NRAS, and PIK3CA in resistance to epidermal growth factor receptor (EGFR)-targeted therapy. The investigators should be congratulated for the scale of their study and the selected chemotherapy-refractory population. Their findings raise the question of whether these results should be immediately implemented in clinical practice. KRAS is currently the only biomarker used to select patients for anti-EGFR monoclonal antibody treatment in clinical practice.